icr.ac.uk
Apr 4, 2025, 07:31
ICR and life sciences company QBiotics Group Limited launch new collaboration
The Institute of Cancer Research (ICR) posted on LinkedIn:
“We’re thrilled to announce an exciting new collaboration.
Scientists in our Centre for Immunotherapy of Cancer are working with life sciences company QBiotics Group Limited on the development of a potential new cancer drug.
Together we are investigating its effects in samples from patients with head and neck cancer taking part in a clinical trial. Fascinatingly, the potential drug – called tignanol tiglate was isolated from the seed of the North Australian blushwood tree.
The seeds piqued the interest of QBiotics’ scientists after they noticed that the musky-rat kangaroo, the world’s smallest kangaroo found the seeds of its fruit unpalatable.
Read more about our collaboration here.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 4, 2025, 07:32
Apr 4, 2025, 07:08
Apr 4, 2025, 06:52
Apr 4, 2025, 06:38